Nano Dimension proposes $890 million merger giving Infinite Epigenetics control of Nasdaq listing

Nano Dimension Ltd. announced on June 15, 2026, that it selected Infinite Epigenetics as the target for a proposed business combination valued at $890 million. The company reached the decision after a multi-month strategic review that assessed approximately 20 potential targets across multiple sectors.

David Stehlin, Chief Executive Officer of Nano Dimension, said Infinite Epigenetics represented the most attractive opportunity to enhance shareholder value. The proposed transaction would deploy Nano Dimension's capital base and Nasdaq listing into a healthcare AI opportunity.

Existing Nano Dimension shareholders are expected to retain a meaningful minority ownership interest in the combined company, based on a stated value for Nano shares that reflects a 20% premium to Nano Dimension's estimated net cash at closing.

U.S. market. Its platform reads more than 1 million epigenetic signals from a single test. Epigenetic gene expression represents approximately 80 percent of one's health, while underlying DNA code accounts for approximately 20 percent.

The company was co-founded by Dr. Matthew Dawson, Dr. Michael Mallin, and Brad Keywell. Keywell is an original investor and board member of Tempus AI, Inc. Infinite Epigenetics operates through subsidiaries TruDiagnostic, a CLIA-certified laboratory founded in 2019, and Tally Health, a consumer longevity and preventative health company founded in 2021.

Infinite Epigenetics is initially focused on cardiovascular disease, Type 2 diabetes, COPD, and MASLD. These four diseases impact more than 4 billion people worldwide. Chronic diseases account for more than $4 trillion in annual healthcare costs.